Scientists at the world-renowned Oxford University in England have just confirmed that hydroxychloroquine (HCQ) is “safe and effective” when used to treat COVID-19.
A study into the effectiveness of the drug against Covid was conducted by the COPCOV Collaborative Group.
The group, led by Dr. William H. K. Schilling, is part of the Mahidol Oxford Tropical Medicine Research Unit (MORU) Tropical Health Network.
The study sought to better understand the safety profile of hydroxychloroquine (HCQ) after multiple reports emerged during the pandemic that the antiviral drug had been successfully used to treat Covid.
The drug is normally used to treat lupus and rheumatoid arthritis.
However, despite previous reports of the drug’s success, guidelines around the world recommend against the use of HCQ for COVID-19.
It has widely been rumored that HCQ was suppressed to protect pharmaceutical industry interests as the cheap and widely available drug showed great promise in treating Covid before mRNA “vaccines” were rolled out for public use in early 2021.
In addition, President Donald Trump touted HCQ as a potential treatment for Covid, which led to a global smear campaign against the drug by the liberal corporate media.
During the Oxford study, the team conducted a large placebo-controlled, double-blind randomized trial with 4,652 patients.
Led by physician-investigators, the study involved the enrollment of healthy adult participants in a healthcare setting, and later from the community across 26 trial sites in 11 countries.
The study found that HCQ and chloroquine (CQ) are not only safe and well tolerated in COVID-19 chemoprevention, but the scientists also found “evidence of moderate protective benefit in a meta-analysis including this trial and similar RCTs.”
This study’s findings mean that, despite all the fearmongering about HCQ, the drug could have been used as a safe, well-tolerated means of at least moderate protection against SARS-CoV-2, the virus that causes Covid.
Many lives could have been saved had this outcome come sooner.
The study’s paper was just published in the medical journal PLOS Medicine.
During the study, the COPCOV investigators assessed HCQ in Europe and Africa, and chloroquine (CQ) in Asia, (both base equivalent of 155 mg once daily).
The primary and safety analyses were conducted in the intention-to-treat (ITT) population.
The intention-to-treat (ITT) population is the group of all patients who were randomized to participate in a clinical trial, regardless of whether they received the intended treatment or completed the trial.
The ITT population is used to analyze the outcomes of a trial and is intended to represent what would happen if the treatment were used in real-world clinical practice
In conclusion of their study, the University of Oxford-led team declared:
“Both drugs were well tolerated with no drug-related serious adverse events (SAEs).”
The authors of this important study acknowledge that it is “unlikely” that CQ or HCQ would be used extensively to protect against COVID-19 moving forward.
However, they note that the drugs “could have been deployed with benefit earlier, and they might have value in future pandemics.”
This randomized controlled trial is game changing, a major turnaround from what was incredible politicization involving this drug and COVID-19.
They concluded that “trials should be facilitated and protected so that evidence is generated rapidly and evidence-based policies can be implemented without delay to allow timely interventions.”
Unfortunately, people were left to die during the pandemic because doctors were banned from treating patients with the politicized drug.
